Anastrozole

證據等級: L5

預測適應症: 10 個

Anastrozole: From Postmenopausal ER-Positive Breast Cancer to Female Breast Carcinoma

One-Sentence Summary

Anastrozole is a third-generation aromatase inhibitor internationally established for the treatment of hormone receptor-positive breast cancer in postmenopausal women, but it is not currently registered with the Australian Therapeutic Goods Administration (TGA).

The TxGNN model predicts it may be effective for Female Breast Carcinoma broadly — encompassing adjuvant, neoadjuvant, advanced, and chemoprevention settings — with 50+ clinical trials and 20 publications currently supporting this direction.

The overall evidence base is among the strongest available for any cancer indication, anchored by landmark Phase 3 trials including ATAC and IBIS-II.

Quick Overview

Item	Content
Original Indication	Not available (Anastrozole is not currently registered in Australia; internationally approved for hormone receptor-positive early and advanced breast cancer in postmenopausal women)
Predicted New Indication	Female Breast Carcinoma
TxGNN Prediction Score	99.68%
Evidence Level	L1
Australia Market Status	Not Registered
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Anastrozole selectively inhibits the aromatase enzyme (CYP19A1), which is responsible for the final step of oestrogen biosynthesis in peripheral tissues — including fat, muscle, liver, and breast tumour stroma. By suppressing circulating and local oestrogen levels, anastrozole deprives oestrogen receptor-positive (ER+) breast cancer cells of their primary growth signal, leading to cell cycle arrest and tumour regression. This mechanism is direct, well-characterised, and underpins its worldwide clinical adoption.

In postmenopausal women, where the ovaries have ceased to be the dominant oestrogen source, peripheral aromatisation becomes the principal oestrogen supply pathway. Anastrozole’s targeted blockade at this point makes it especially effective in this population. The landmark ATAC trial (>9,000 postmenopausal women, 5-year adjuvant therapy) demonstrated statistically significant improvement in disease-free survival compared to tamoxifen, establishing anastrozole as a preferred adjuvant agent. The IBIS-II prevention trial further demonstrated a sustained 49% reduction in breast cancer incidence in high-risk women followed for over 10 years.

The TxGNN model’s prediction for “female breast carcinoma” is strongly supported: it encompasses ER+ early-stage adjuvant therapy, neoadjuvant downsizing for operable disease, first-line treatment for advanced/metastatic disease, chemoprevention of ductal carcinoma in situ (DCIS), and combination strategies with CDK4/6 inhibitors (palbociclib, abemaciclib, ribociclib) or other novel agents. For triple-negative breast cancer (TNBC), which lacks ER expression, the mechanistic rationale is weak in monotherapy but anastrozole has been explored in combination approaches targeting co-drivers such as HDAC inhibition. The TGA has not yet registered anastrozole in Australia despite robust global evidence — making this a high-priority regulatory consideration.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT01953588	Phase 3	Active, Not Recruiting	1,473	ALTERNATE trial: neoadjuvant anastrozole vs fulvestrant vs combination in Stage II/III ER+/HER2- breast cancer; directly evaluates anastrozole as pre-surgical endocrine therapy
NCT00143390	Phase 3	Completed	298	Exemestane vs anastrozole as initial hormonal therapy in advanced/recurrent breast cancer; confirms non-inferiority and establishes anastrozole’s clinical role in this setting
NCT02338310	Phase 3	Active, Not Recruiting	4,486	POETIC trial: perioperative aromatase inhibitor (including anastrozole) followed by standard adjuvant therapy; evaluates Ki67 as a predictor of time to recurrence
NCT00635713	Phase 3	Completed	588	Double-blind RCT comparing fulvestrant 125/250 mg vs anastrozole 1 mg in advanced breast cancer; key benchmark trial for anastrozole’s efficacy in the advanced setting
NCT04711252	Phase 3	Active, Not Recruiting	1,370	SERENA-4: camizestrant + palbociclib vs anastrozole + palbociclib as first-line therapy in ER+/HER2- advanced breast cancer; uses anastrozole as the active comparator gold standard
NCT02206984	Phase 2	Completed	201	Endocrine response in invasive lobular carcinoma (ILC); supports anastrozole benefit in this distinct breast cancer subtype
NCT00256217	Phase 2	Completed	42	Anastrozole chemoprevention in DCIS and early invasive breast cancer in postmenopausal women; complementary to IBIS-II prevention data
NCT04075604	Phase 2	Completed	23	Neoadjuvant nivolumab + palbociclib + anastrozole in ER+/HER2- breast cancer; evaluates novel immunotherapy combination with anastrozole as the endocrine backbone
NCT01234532	Phase 2	Terminated	5	Entinostat + anastrozole in triple-negative breast cancer; exploratory HDAC combination strategy; early termination limits conclusions
NCT04767594	N/A (Observational)	Active, Not Recruiting	1,409	PERFORM: real-world prospective cohort of HR+/HER2- advanced breast cancer on palbociclib + endocrine therapy (including anastrozole); provides safety and effectiveness data in routine clinical practice

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31839281	2020	Phase 3 RCT (Prevention)	Lancet	IBIS-II long-term follow-up: anastrozole reduces breast cancer incidence by 49% in high-risk postmenopausal women; sustained benefit beyond the 5-year treatment period
15639680	2005	Phase 3 RCT	Lancet	ATAC trial 5-year results: anastrozole significantly improves disease-free survival vs tamoxifen in postmenopausal women with localised breast cancer (HR 0.87); fewer serious adverse effects
28614542	2017	Systematic Review	Rev Assoc Med Bras	Comprehensive review of anastrozole in chemoprevention and treatment; confirms potent, selective aromatase inhibition with favourable pharmacokinetics and superior efficacy over tamoxifen across multiple settings
24716940	2014	Meta-analysis of RCTs	Asian Pac J Cancer Prev	Meta-analysis comparing fulvestrant 250 mg vs anastrozole 1 mg in advanced breast cancer; provides pooled efficacy and tolerability data supporting anastrozole’s established role
20923259	2010	Drug Review	Expert Opin Drug Safety	Safety profile review of anastrozole in the adjuvant setting; multiple RCTs show greater efficacy than tamoxifen; highlights musculoskeletal and bone density considerations
16439860	2006	Review	Oncology	Reviews anastrozole across the full breast cancer continuum — from advanced disease to early cancer and prevention; outlines survival benefits and tolerability advantages
16761927	2006	Review	Expert Rev Anticancer Ther	ATAC-focused clinical update; confirms anastrozole’s significant efficacy and tolerability advantages as initial adjuvant treatment in postmenopausal hormone receptor-positive breast cancer
14687437	2003	Review	Curr Med Res Opin	Overview of anastrozole’s evolving role in breast cancer management; confirms superiority over megestrol acetate and medroxyprogesterone as second-line treatment, and comparability to tamoxifen as first-line
21508387	2011	Pharmacodynamic Study	Anticancer Research	Characterises anastrozole’s effect on steroid sulfatase activity and serum androgen concentrations; provides mechanistic insight into the broader hormonal milieu altered by aromatase inhibition
41024216	2025	Case Report / Mechanism Study	J Med Case Reports	Documents a case where anastrozole-induced hormonal changes (decreased oestrogen, increased dihydrotestosterone) may have contributed to development of apocrine mammary carcinoma and follicular lymphoma; highlights importance of long-term monitoring

Australia Market Information

Anastrozole is currently not registered with the Australian TGA and has no active ARTG entries in the database queried. There are no approved product entries to display.

Note for clinicians: Despite the absence of TGA registration at the time of this data extract, anastrozole is widely approved by comparable international regulators including the US FDA, EMA (Europe), PMDA (Japan), and Health Canada. Generic anastrozole is available globally. The absence of ARTG entries may reflect a data collection gap rather than a clinical availability gap — TGA registration status should be verified directly via the TGA ARTG Public Summary.

Cytotoxicity

Anastrozole is an anticancer drug but is not a conventional cytotoxic agent. It acts via targeted endocrine modulation rather than direct DNA damage or cell killing.

Item	Content
Cytotoxicity Classification	Non-cytotoxic — Targeted endocrine therapy (Third-generation non-steroidal aromatase inhibitor)
Myelosuppression Risk	Low — Aromatase inhibitors do not cause clinically significant myelosuppression; bone marrow toxicity is not a recognised class effect
Emetogenicity Classification	Minimal — Oral tablet; nausea is uncommon and rarely clinically significant
Monitoring Items	Bone mineral density (DEXA scan at baseline and periodically — AI-induced bone loss is a key concern); lipid profile; liver function tests (if clinically indicated); musculoskeletal symptom assessment (arthralgia, myalgia)
Handling Protection	Standard oral medication precautions apply; NOT classified as a cytotoxic drug requiring specialised handling under hazardous drug regulations — standard dispensing and administration procedures are appropriate

Safety Considerations

Specific safety data (TGA-approved warnings, contraindications, and drug interaction records) were not available in this Evidence Pack.

Please refer to the TGA-approved Product Information (PI) and the internationally available manufacturer’s PI (e.g., Arimidex® PI) for comprehensive safety information, including known musculoskeletal effects, bone density loss, cardiovascular considerations, and interactions with oestrogen-containing products and tamoxifen.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The evidence base for anastrozole in female breast carcinoma is among the most robust in oncology — multiple completed Phase 3 RCTs (ATAC, IBIS-II, and others) demonstrate superiority over tamoxifen in postmenopausal ER-positive disease, and the mechanistic rationale (CYP19A1 inhibition → oestrogen suppression → ER+ tumour regression) is well-established and directly validated. The primary barrier is the absence of current TGA registration in Australia, not a lack of efficacy evidence.

To proceed, the following is needed:

TGA Registration Verification: Confirm whether anastrozole is registered in Australia under the ARTG (the current data showing 0 entries may reflect a data collection gap — anastrozole generics are widely marketed internationally)
Formal MOA Documentation: Obtain DrugBank API data for official mechanism of action, drug categories, and toxicity classifications to complete the evidence dossier
TGA Product Information (PI) Review: Retrieve and review the TGA-approved or internationally available PI for complete warnings, contraindications, special population data (pregnancy, renal/hepatic impairment), and drug interactions
Bone Health Management Plan: Given the well-documented risk of AI-induced bone loss, any Australian clinical programme should include a DEXA monitoring protocol and bisphosphonate co-prescription criteria (as evaluated in NCT00122356 with alendronate)
Population Stratification: Clarify the intended patient population — ER+ vs TNBC vs prevention — as the mechanistic rationale and evidence strength differ substantially across these subgroups
Regulatory Pathway Assessment: If TGA registration is confirmed absent, determine whether a TGA submission, compassionate access application, or reliance pathway (based on FDA/EMA approval) is the most efficient route to market authorisation

This report is generated for research purposes only. Drug repurposing candidates require clinical validation before therapeutic application. All treatment decisions must be made by qualified healthcare professionals in accordance with current TGA-approved guidelines. Data cutoff: 5 April 2026.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.